Last reviewed 2026-04-23 · How we verify

JKN2301 Dry Suspension

JKN2301 is an investigational dry suspension formulation designed to improve bioavailability and patient compliance for an undisclosed active pharmaceutical ingredient.

At a glance

Mechanism of action

Without publicly available information on the active pharmaceutical ingredient or mechanism of action, the primary innovation appears to be the dry suspension formulation technology developed by Joincare Pharmaceutical Group. This formulation approach typically aims to enhance drug stability, enable easier administration, and improve absorption compared to conventional liquid or solid dosage forms.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• JKN2301 Dry Suspension CI brief — competitive landscape report
• JKN2301 Dry Suspension updates RSS · CI watch RSS
• Joincare Pharmaceutical Group Industry Co., Ltd portfolio CI